Plain-English translation of NCT07132684 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a newer combination called + works as well as or better than a traditional chemotherapy combination (Daunorubicin or Idarubicin plus ) in older adults with acute myeloid leukemia—a serious blood cancer. You would be randomly assigned to receive one of these two treatment approaches. The goal is to find which medication combination helps people survive longer and with fewer side effects.
Acute myeloid leukemia is a life-threatening cancer, and while traditional chemotherapy has been the standard treatment for decades, newer drug combinations may offer better outcomes with potentially fewer severe side effects. This trial will help doctors understand which approach is safest and most effective for older patients.
You likely qualify if…
You likely don't qualify if…
You will receive chemotherapy drugs either by injection or by mouth as an outpatient or during hospital stays, depending on which treatment group you are assigned to. The initial treatment phase lasts several weeks, followed by additional cycles of consolidation and maintenance therapy over several months. You will have regular blood tests, imaging scans, and doctor visits to monitor how well the treatment is working and to manage any side effects. Your total participation will span several months to over a year.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Enrollment target
~240 participants
Started
August 2025
Primary completion
August 2027
Age range
55 Years – 75 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hui Wei, MD
Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.